Skip to main content
AVCRF
OTC Life Sciences

HealthTab™ Goes National: NHS England Backs Avricore's Pharmacy Cholesterol Testing

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.001
Mkt Cap
$5.417M
52W Low
$0.001
52W High
$0.079
52W Position info
0.0% above low
Off High info
99% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

AVCRF is trading near its 52-week low of $0.001 (0.0% above the low) on light trading volume (0.3× avg).

Summary

NHS England will expand Avricore Health's HealthTab™-powered cholesterol testing programme nationally across England, starting with approximately 100 pharmacies this fall.


Key Events · M&A and Partnerships · AVCRF

  • NHS England Confirms National Expansion

    NHS England confirmed the national expansion of the Barts Health pharmacy cholesterol testing programme powered by Avricore's HealthTab™ platform, with approximately 100 pharmacies across England beginning seven-minute cholesterol checks this fall.

  • Pilot Programme Demonstrated Clinical Impact

    The north London pilot tested 2,493 patients across 61 community pharmacies between January 2025 and March 2026, identifying 19% as high risk for heart attack or stroke within a decade, with at least 88 patients subsequently beginning statin therapy.

  • First National Phase Runs Until Spring 2027

    The first national phase of the NHS initiative will run until spring 2027, providing a multi-year revenue runway for HealthTab™ deployments across England.

  • Follows Abbott Collaboration Announced September 16

    This national expansion follows the September 16, 2026 announcement of a multi-year collaboration with Abbott to distribute point-of-care testing products in UK pharmacies, reinforcing the company's UK growth strategy.


Analysis · AVCRF · Life Sciences

A major commercial validation has arrived for Avricore Health, a micro-cap trading near its 52-week low. NHS England confirmed a national rollout of the Barts Health pharmacy cholesterol testing programme powered by Avricore's HealthTab™ platform. Approximately 100 pharmacies will begin offering seven-minute cholesterol checks this fall, with the first national phase running until spring 2027. This follows the September 16 Abbott collaboration announcement, suggesting the UK point-of-care testing strategy is gaining real traction.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AVCRF was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $0.00 to $0.08. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AVCRF - Latest Insights

AVCRF
Sep 16, 2026, 6:02 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.000801
Real-time Price: $0.0008 info
Change: -$0.000001 (-0.12%) info
Market Cap: $4.006M info
AVCRF
Jul 10, 2026, 8:19 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.056
Real-time Price: $0.0008 info
Change: -$0.0552 (-99%) info
Market Cap: $4.006M info
AVCRF
Jun 11, 2026, 6:12 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.04965
Real-time Price: $0.0008 info
Change: -$0.04885 (-98%) info
Market Cap: $4.006M info
AVCRF
May 08, 2026, 7:01 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.0399
Real-time Price: $0.0008 info
Change: -$0.0391 (-98%) info
Market Cap: $4.006M info
AVCRF
Feb 17, 2026, 6:15 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.0529
Real-time Price: $0.0008 info
Change: -$0.0521 (-98%) info
Market Cap: $4.006M info